Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1631-1636

  Boucher, Paul D ^a   Ostruszka, Leo J ^a   Shewach, Donna S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGUANOSINE TRIPHOSPHATE; GANCICLOVIR; HYDROXYUREA; THYMIDINE KINASE;

ARTICLE; COLON CARCINOMA; CYTOTOXICITY; HERPES VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COCULTURE TECHNIQUES; DEOXYRIBONUCLEOTIDES; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GANCICLOVIR; HUMANS; HYDROXYUREA; INHIBITORY CONCENTRATION 50; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0034654516     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
2. Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., and Collins, M. K. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer, 31A: 2362-2370, 1995.
3. Mullen, C. A., Kilstrup, M., and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA, 89: 33-37, 1992.
4. Moolten, F. L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46: 5276-5281, 1986.
5. Balzarini, J., Bohman, C., and DeClercq, E. Differential metabolism of cytostatic of (E)-5-(2-bromoviny])-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J. Biol. Chem., 269: 6332-6337, 1993.
6. Ilsley, D. D., Lee, S-H., Miller, W. H., and Kuchta, R. D. Acyclic guanosine analogs inhibit DNA polymerases a, d, and Î with very different potencies and have unique mechanisms of action. Biochemistry, 34: 2504-2510, 1995.
7. Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham. G. N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53: 5274-5283, 1993.
8. DiMaio, J. M., Clary, B. M., Via, D. F., Coveney, E., Pappas, T. N., and Lyerly, H. K. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery, 116: 205-213, 1994.
9. Ezzeddine, Z. D., Martuza, R. L., Platika, D., Short, M. P., Malick, A., Choi, B., and Breakefield, X. O. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol., 3: 608-614, 1991.
10. Caruso, M., Panis, Y., Gagandeep, S., Houssin, D., Salzmann, J-L., and Klatzmann, D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA, 90: 7024-7028, 1993.
11. Ram, Z., Culver, K. W., Walbridge, S., Blaese, R. M., and Oldfield, E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53: 83-88, 1993.
12. Vile, R. G., and Hart, I. R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53: 3860-3864, 1993.
13. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki. S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res., 55: 3105-3109, 1995.
14. O'Malley, B. W., Jr., Chen, S-H., Schwartz, M. R., and Woo, S. L. C. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res., 55: 1080-1085, 1995.
15. Yoshida, K., Kawami, H., Yamaguchi, Y., Kuniyasu, H., Nishiyama, M., Hirai, T., Yanagihara, K., Tahara, E., and Toge, T. Retrovirally transmitted gene therapy for gastric carcinoma using herpes simplex virus thymidine kinase gene. Cancer (Phila.), 75: 1467-1471, 1995.
16. Roth, J. A., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst., 89: 21-39, 1997.
17. Denning, C., and Pitts, J. D. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum. Gene Ther., 8: 1825-1835, 1997.
18. Rubsam, L. Z., Boucher, P. D., Murphy, P. J., KuKuruga, M., and Shewach, D. S. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type I thymidine kinase-expressing human glioblastoma cells. Cancer Res., 59: 669-675, 1999.
19. Bi, W. L., Parysek, L. M., Warnick, R., and Stambrook, P. J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum. Gene Ther, 4: 725-731, 1993.
20. Boucher, P. D., Ruch, R. J., and Shewach, D. S. Differential ganciclovir-medialed cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum. Gene Ther., 9: 801-814, 1998.
21. Machado, S. G., and Robinson, G. A. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat. Med., 13: 2289-2309, 1994.
22. Griffiths, G. M., Berek, C., Kaartinen, M., and Milstein, C. Somatic mutation and maturation of immune response to 2-phenyl-oxazolone. Nature (Lond.), 312: 271-275, 1984.
23. Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chriswell, D. J., Hudson, P., and Winter, G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res., 19: 4133-4137, 1991.
24. Coloma, M. J., Hastings, A., Wims, L. A., and Morrison, S. L. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J. Immunol. Methods. 152: 89-104, 1992.
25. Samejima, Y., and Meruelo, D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Ther., 2: 50-58, 1995.
26. Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., and Yamasaki, H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc. Natl. Acad. Sci. USA, 93: 1831-1835, 1996.
27. Elshami, A. A., Saavedra, A., Zhang, H., Kucharczuk, J. C., Spray, D. C., Fishman, G. L., Amin, K. M., Kaiser, L. R., and Albelda, S. M. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther., 3: 85-92, 1996.
28. Yeager, M., and Nicholson, B. J. Structure of gap junction intercellular channels. Curr. Opin. Struct. Biol., 6: 183-192, 1996.
29. Fick, J., Barker, F. G. I., Dazin, P., Westphale, E. M., Beyer, E. C., and Israel, M. A. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. USA, 92: 11071-11075, 1995.
30. Yang, L., Chiang, Y., Lenz, H., Danenberg, K. D., Spears, C. P., Gordon, E. M., Anderson, W. F., and Parekh, D. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther., 9: 719-728, 1998.
31. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther., 8: 73-85, 1997.
32. Aghi, M., Kramm, C. M., Chou, T., Breakefield, X. O., and Chiocca, E. A. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J. Natl. Cancer Inst., 90: 370-380, 1998.
33. Gwilt, P. R., and Tracewell, W. G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet., 34: 347-358, 1998.
34. Donehower, R. C. Hydroxyurea. In: B. A. Chabner, and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 253-261. Philadelphia: Lippincott-Raven Publishers, 1996.
35. Bianchi, V., Pontis, E., and Reichard, P. Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J. Biol Chem., 261: 16037-16042, 1986.
36. Rubsam, L. Z., Davidson, B. L., and Shewach. D. S. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res., 58: 3873-3882, 1998.
37. Yoshioka, A., Tanaka, S., Osamu, H., Koyama, Y., Hirota, Y., Ayusawa, D., Seno, T., Garrett, C., and Wataya, Y. Deoxyribonucleoside triphosphate imbalance. J. Biol. Chem., 262: 8235-8241, 1987.
38. 1/S transition state enzyme, in p53-mutated cells. Biochem. Pharmacol., 55: 1353-1360, 1998.
39. Collins, A., and Oates, D. J. Hydroxyurea: effects on deoxyribonucleotide pool sizes correlated with effects on DNA repair in mammalian cells. Eur. J. Biochem., 169: 299-305, 1987.